Introduction
There is no doubt that the identification of an inducible isoform of cyclooxygenase (here referred to as cyclooxygenase-2 or COX-2) has brought about a renaissance in prostanoid biochemistry, pharmacology and therapeutics. This area is now as vigorous as it was 20 years ago when thromboxane A2 (TXA2) and prostacyclin (PGI2) were discovered 1'2 and indeed is almost as active as that of nitric oxide (NO), with which it shares many features and correlations. One of the most important features of COX-2 is its close association with a variety of inflammatory mediators and its consequent description as the COX isoform involved in and responsible for many of the signs of inflammation. It is also generally accepted that COX-1 is the constitutive isoform involved in the physiological actions of prostaglandins (PGs) in the stomach and kidney, the inhibition of which leads to gastric ulceration and nephropathy as side effects of anti-inflammatory therapy with nonsteroidal anti-inflammatory drugs (NSAIDs).
The initial findings and many of the subsequent developments are based on the techniques of molecular biology 3'4 and are often expressed in terms unfamiliar to many researchers already established in inflammation. Our purpose in this review is to summarize the progress made so far in characterizing the regulation of COX-2, to evaluate its role in inflammation and, as a consequence, to assess the utility of the selective inhibitors of COX-2. In order to establish the appropriate context for the analysis of regulatory mechanisms, we shall (C) 1996 Rapid Science Publishers first consider the molecular biochemistry of COX-2 and its possible place in physiology. We shall also refer to work on COX-1 where necessary.
Molecular Biochemistry of COX-2
Although the early work on COX-2 utilized animal sources, information relating to the human form of this enzyme is steadily accumulating. Since the practical outcome of COX-2 research would be the more efficient alleviation of human inflammatory conditions, emphasis will be placed on results obtained with the human protein, along with data from animal sources wherever relevant. Here, for clarity and simplicity, the molecular biochemistry of COX-2 will be considered at three separate levelsmits DNA, its RNA and the enzyme protein; further details of the molecular biolog.y 4 of COX-2 are available in two recent reviews. 3' 
DNA
The gene for COX-2 is located on chromosome 1 in both human and mouse cells. [5] [6] [7] [8] The small size of the COX-2 gene (7. 6 '7'9'6'7 the corresponding region of the mouse gene appears to lack a CRE, 4 NFkB or NF-IL6 site, 7 although the others are present. The rat gene which has over 80% identity with the mouse gene in this region also lacks CRE, NFkB or AP-2 sites and a TATA box but includes a site for NF-IL6. &19 However more recent analysis of the mouse gene for COX-2 in an osteoblastic cell line has found an action of and sites for, NFkB; the same authors have also 20 identified a NFkB binding site in the rat gene. mRNA Reflecting the similarity in cDNA for COX-2 across species, there is also considerable similarity in mRNA for COX-2, which at 4 kb is almost twice the size of that for COX-1 (2.8 kb) in all 21 species so far examined. Since the enzyme proteins (COX-1 and COX-2) are very similar in size, just over 600 amino acid residues, most of the difference in mRNA for COX-1 and COX-2 is taken up by the extensive 3'-untranslated region in COX-2 mRNA. This region includes several copies of the Shaw-Kamen 'instability' sequence, the actual number varying 2 between species from 14 to 18 in animals. 2 In two examples of human mRNA, 17 and 22 copies were found.7'9 These sequences are characteristic of rapidly degraded RNA 7 '9 and have been found in the mRNA for other immediate early proteins. 2 However such sequences do not occur in the mRNA for COX-1 in any species.
Estimates of the half-life of COX-2 mRNA vary with the cells studied and with the stimuli used for induction of the protein.
In an endothelium- 24 derived cell line (ECV304) with IL-1 as the Table 2 ). The sulphonamide grouping is present in all except meloxicam in which it forms part of a cyclic structure. None of these compounds has a carboxylic acid grouping characteristic of the 'older' NSAIDs.
insert at the C-terminus. 
